Spero Therapeutics Inc (SPRO) support and resistance · P/E 9.6, rev $48.0M
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
This page maps Spero Therapeutics Inc (SPRO) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
SPRO currently screens at market cap $149.5M and trailing P/E 9.6. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new SPRO 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the SPRO quote page for the session range and the stock page for the full model.
Not investment advice.